中基長壽科學(00767.HK)與華驪生命成立合資公司 從事於中國提供長壽健康服務
格隆匯4月1日丨中基長壽科學(00767.HK)發佈公吿，於2025年4月1日，公司全資附屬公司深圳市中基健康科學有限公司（中基健康）與華驪（廣東）生命科學技術有限公司（華驪生命）簽訂有關於中國成立一間合資公司的合資協議，合資公司於成立時將由中基健康擁有51%及華驪生命擁有49%的股權。合資公司將主要從事於中國提供長壽健康服務。
合資公司的初始註冊資本為人民幣1,000,000元，將由中基健康及華驪生命按彼等各自於合資公司的權益比例出資。
華驪生命是一家於2022年於中國成立的有限公司。華驪生命作為中國首屈一指的，以「會議驅動產業生態」為核心發展模式的創新型科技企業，專注於通過「造會、辦會、轉化」的全鏈閉環運營體系，重塑生命科學領域資源的流通與整合效率，而且在舉辦長壽大健康展會等領域有着豐富的經驗，客户資源豐富，成功舉辦了多場在生命科學領域具有全球影響力的頂級會議，例如第一屆及第二屆博鰲樂城幹細胞大會、世界生命科學大會和即將召開博鰲樂城首屆前沿生物技術醫學大會等。作為生命科學領域的國際盛會，匯聚了全球頂尖專家學者與行業精英，吸引了來自世界各地的科研人員、企業代表踴躍參與，極大地推動了生命科學領域的交流與發展。華驪生命依託先進的AI、區塊鏈技術、以資料為關鍵紐帶，全力打造全球領先的「會議即生產力」平台，為政府部門、醫療機構、科研院所及企業提供集「資源匹配、技術轉化、商業落地」為一體的一站式綜合解決方案。
成立合資公司符合集團的長壽科學業務發展策略及計劃，將有利於集團未來的業務發展。合資公司將打造全球領先的生命科學產業賦能平台，構建「學術會議、技術轉化、產業落地」位一體生態鏈，推動中國生命科學領域產學研深度融合。董事會相信合資協議進一步完善集團在長壽科學診斷及醫療服務領域的佈局，為公司開拓新的長壽科學收入來源，以期長遠為集團帶來更加穩定及持續增長的收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
